{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-173985","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.480267+00:00","generated_at":"2026-05-17T19:30:23.667942+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Seres Q2 net loss narrows to $19.9M; CEO replaced; SER-155 Phase 2 protocol filed","bullets":["Net loss from continuing ops $19.9M in Q2 2025 vs $26.2M in Q2 2024; cash $45.4M as of June 30.","Received $25M Nestlé installment in July; expects cash runway into Q1 2026.","Co-CEOs Thomas DesRosier and Marella Thorell appointed Aug 1 after prior CEO Eric Shaff departed.","SER-155 Phase 2 protocol submitted to FDA for BSI prevention in allo-HSCT; awaiting FDA feedback.","Engaging with multiple parties on partnerships, out-licensing, or mergers to secure capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-173985","json":"https://secwatch.observer/filing/0001193125-25-173985.json","markdown":"https://secwatch.observer/filing/0001193125-25-173985.md","text":"https://secwatch.observer/filing/0001193125-25-173985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525173985/0001193125-25-173985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525173985/d930624d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:30:23.667942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}